

1
2
3
4

TITLE PAGE
- Korean Journal for Food Science of Animal Resources -
Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
Article Title	Preparation and Characterization of a Polar Milk Lipid-Enriched Component from Whey Powder
Running Title (within 10 words)	A polar milk lipid-enriched compound from whey powder
Author	Kwanhyoung Lee ^{1,2} , Ara Kim ¹ , Ki-Bae Hong ³ , Hyung Joo Suh ⁴ , Kyungae Jo ⁴
Affiliation	1 Doosan Corporation, Solus, Suwon 16229, Republic of Korea 2 Department of Integrated Biomedical and Life Sciences, Graduate School, Korea University, Seoul 02841, Republic of Korea 3 Dongduk Women's University, Seoul 02748, Republic of Korea 4 BK21 Plus, College of Health Science, Korea University, Seoul 02841, Republic of Korea
Special remarks – if authors have additional information to inform the editorial office	
ORCID (All authors must have ORCID) https://orcid.org	Kwanhyoung Lee (https://orcid.org/0000-0002-2251-7698) Ara Kim (https://orcid.org/0000-0003-1646-5382) Ki-Bae Hong (https://orcid.org/0000-0001-5199-2685) Hyung Joo Suh (https://orcid.org/0000-0001-8869-3929) Kyungae Jo (https://orcid.org/0000-0003-4056-6706)
Conflicts of interest List any present or potential conflicts of interest for all authors. (This field may be published.)	The authors declare no potential conflict of interest.
Acknowledgements State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available. (This field may be published.)	
Author contributions (This field may be published.)	Conceptualization: Suh HJ. Data curation: Jo KA. Formal analysis: Jo KA. Methodology: Suh HJ. Software: Hong KB. Validation: Lee KY. Investigation: Kim A. Writing - original draft: Suh HJ. Writing - review & editing: Lee KH, Kim A, Hong KB, Suh HJ, Jo KA.
Ethics approval (IRB/IACUC) (This field may be published.)	This manuscript does not require IRB/IACUC approval because there are no human and animal participants.

5
6

CORRESPONDING AUTHOR CONTACT INFORMATION

For the <u>corresponding</u> author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Kyungae Jo and Hyung Joo Suh
Email address – this is where your proofs will be sent	kyungae11@korea.ac.kr, suh1960@korea.ac.kr
Secondary Email address	jo-kyung-ea@hanmail.net, foodsuh@naver.com
Postal address	BK21 Plus, College of Health Science, Korea University, Seoul 02841, Republic of Korea

Cell phone number	+82 10 9253 7595, +82 10 4214 2853
Office phone number	+82 2 940 2764
Fax number	+82 2 921 7207

7
8

ACCEPTED

9 **Abstract**

10 Milk fat globule membrane (MFGM) is a lipid carrier in mammals including humans that consists
11 mainly of polar lipids, like phospholipids and glycolipids. In this study, a process to enrich polar lipids
12 in commercial butter and whey powder, including polar lipids of MFGM, was developed. WPC (whey
13 protein concentrate) 60 was selected as the most suitable raw material based on the yield, phospholipid,
14 protein, and lactose content of the polar lipid fraction obtained by ethanol extraction of two WPC
15 (WPC60 and WPC70) and two buttermilk (A and B). After fractionation under optimum conditions, the
16 polar-lipid enriched fraction from WPC60 contained 38.56% phospholipids. The content of glycolipids,
17 cerebroside, lactosylceramide, ganglioside GM3, ganglioside GD3, was 0.97%, 0.55%, 0.09%, and
18 0.14%, respectively. Rancimat results showed that the oxidation stability of fish oil increased with an
19 increase in the polar-lipid fraction by more than 30 times. In addition, the secretion of IL-6 and TNF- α
20 decreased in a concentration-dependent manner after treatment of RAW 264.7 cells with 0.1 to 100 ppm
21 of the polar lipid fraction. In this study, polar lipid concentrates with antioxidant and anti-inflammatory
22 activity, were prepared from milk processing by-products. The MFGM polar lipid concentrates made
23 from by-products are not only additives for infants, but are also likely to be used as antioxidants in
24 cooking oils and as active ingredients for functional foods.

25 **Keywords:** MFGM, polar lipids, whey powder, rancimat, anti-inflammatory

26

27 **Introduction**

28 Polar fats present in the milk fat globule membrane (MFGM), together with cholesterol and
29 different proteins, are of nutritional and functional interest. The MFGM consists of a complex mixture
30 of protein, polar, and nonpolar lipids, which constitute up to 90% of its dry weight (El-Loly, 2011). The
31 most polar lipids in MFGM are phospholipids [phosphatidylcholine (PC), phosphatidylethanolamine
32 (PE), phosphatidylinositol (PI), and phosphatidylserine (PS)] and sphingolipids (SM) (Bourlieu et al.,
33 2018). Polar lipids are a major component of the cell membranes and are known to affect health as they
34 play a fundamental role in cell membrane function. Dairy phospholipids (PLs) have been shown to
35 reduce cholesterol, cardiovascular disease, inflammation and gastrointestinal infections, stress, and
36 cancer, and are also known to affect neuronal differentiation (Contarini and Povolò, 2013).

37 The MFGMs containing polar lipids are released into the water phase by various mechanical
38 treatments, such as heating, stirring, homogenization, or aeration during the manufacture of butter or
39 cheese. Polar lipids in milk can be recovered from whey (Price et al., 2018), a by-product of cheese
40 making, and butter serum (Rombaut et al., 2006b), a by-product of butter making.

41 Most of the recent commercial polar lipids are made from egg yolk and soybean. The low content
42 of PL in dairy products makes it difficult to extract and concentrate PL on an industrial scale. Therefore,
43 microfiltration and ultrafiltration are used to separate polar lipids from dairy products in MFGM
44 fragments and lipoprotein particles. Polar lipids are easily separated from the serum phase by tangential
45 micro- and ultrafiltration techniques that involve addition of water in a step by step manner to remove
46 undesirable components, such as lactose, whey-proteins, and minerals (dialysis filtration) (Gassi et al.,
47 2016). Supercritical fluid extraction has been reported to increase milk polar lipid content by selective
48 removal of neutral lipids (e.g., Triglycerides). To increase the polar lipid content of MFGM obtained
49 through microfiltration, the use of supercritical carbon dioxide was employed, which reduced the
50 concentration of neutral lipids from 21% to 4%, and the concentration of polar lipids increased from
51 9.6% to 19.7% (Astaire et al., 2003). However, these methods require a relatively high cost and have
52 limitations on equipment, which makes industrial access difficult (Price et al., 2018).

53 Generally, for polar lipid extraction, it is suitable to use mixtures of hydrophobic and hydrophilic
54 solvents. Hydrophobic solvent hexane or chloroform and hydrophilic solvent propanol or methanol are
55 used (Le et al., 2011; Rombaut et al., 2005). Triglycerides require hydrophobic solvents for extraction,
56 while amphiphilic polar lipid can be effectively extracted with a mixture of hydrophobic and
57 hydrophilic solvents. However, non-polar solvents present a safety risk, and the use of solvents, like
58 methanol, in the production of food materials is inadequate. Thus, a combination of water, preferably
59 ethanol, is advantageous as a non-polar solvent and a polar counterpart.

60 Therefore, in this study, the extraction of butter serum and whey was evaluated to select suitable raw
61 materials for polar lipid extraction. In addition, the optimum extraction process was established by
62 comparing the polar lipid extraction rate according to the ethanol concentration and solid content.
63 Finally, component analysis was performed and the anti-inflammatory activity of the polar lipids
64 produced by the optimal extraction process was measured.

65 **Materials and methods**

66 **Preparation of the milk phospholipid-enriched ingredient**

67 To prepare the phospholipid-enriched component, butter serums powder A and B were purchased
68 from Corman (Limbourg, Belgium), and whey serum WPC60 and WPC70 were purchased from
69 Agropur Inc. (Saint-Hubert, Quebec).

70 Polar lipids extraction was performed using 85, 90, and 95% ethanol solution (60 L), instead of water,
71 and powdered butter serums or whey serums (10 kg). Extraction was performed for 5 h, with stirring at
72 80-100 rpm at 60°C. After extraction, the mixture was separated into filtrate and precipitate using a 0.45
73 µm membrane filter (Whatman, UK). The filtrate was concentrated using a forced thin-film evaporator
74 (EYELA, Japan). After concentration, the mixture was allowed to stand at 40°C for 30 min, and
75 phospholipids and triacylglycerol were separated into an upper layer and a lower layer. The upper layer
76 was used as the enriched polar lipid fraction.

77 **Composition analysis**

78 The dry matter content was measured by the hot air oven method (IDF, 1983). Total lipid content

79 was estimated gravimetrically using Röse-Gottlieb extraction (IDF, 1996). Protein content was
80 measured using the Kjeldahl nitrogen determination method (IDF, 2001), and by using a protein
81 conversion factor of 6.38. The ash content of the sample was obtained by ingesting 5 g of the sample at
82 550°C, cooling it to room temperature in a desiccator, and measuring the weight. Lactose was analyzed
83 by the AOAC method and HPLC (Zygmunt et al., 1982). High-pressure liquid chromatography (HP
84 1100, Agilent, Massy, France) analysis was performed under the following conditions: the column was
85 an Econosphere NH₂ column (5 µm, 250 mm × 4.6 m; Alltech Associate, Deerfield, Illinois), the mobile
86 phase comprised acetonitrile and water (75:25, v/v) at a flow rate of 1 mL/min and the column
87 temperature was 35°C.

88 **Phospholipid assay by HPLC**

89 The HPLC- evaporative light-scattering detector (ELSD) analysis was carried out using an HPLC
90 (Shimadzu, Kyoto, Japan) instrument equipped with two LC-10 Advp pumps, SCL-10 Advp gradient
91 system, DGU-14 Advp module degasser, and Rheodyne manual injector with a 10 µL sample loop. The
92 analytical column (150 mm × 4.6 mm I.D. 3 µm) was packed with a silica normal-phase Spherisob SIL
93 (Waters Technologies, Milford, MA, USA). Chromatographic separation was carried out using a linear
94 binary gradient, according to the following scheme, 0 min: 4% B, 4 min: 12% B, 12 min: 94% B, and
95 17 min: 4% B. The total run time was 30 min per sample. Eluent A consisted of chloroform and eluent
96 B consisted of methanol and acetic acid-triethylamine buffer (pH 4.5, acetic acid-triethylamine-water,
97 7.2/8.0/118, v/v/v). The flow rate of the eluent was 0.5 mL/min. An ELSD 2000 (Alltech Co. Ltd.,
98 Deerfield, IL) was used; the pressure of nebulizer gas (air) was maintained at 2.2 bar, and the drift tube
99 temperature was set at 100°C.

100 **Rancimat test**

101 Oxidation induction time was measured using Rancimat 743 (Metrohm, Herisau, Switzerland), in
102 accordance with Cha and Choi's method (1990), to determine the degree of rancidity upon heating of
103 the whey protein concentrate (WPC). The sample (3 g) was oxidized by injecting air at a rate of 20 L/h
104 at 100°C. The experiment was repeated three times to determine the degree of rancidity. In order to

105 measure the oxidative stability of phospholipid from whey (WPL), 5% of WPL was added to
106 docosahexaenoic acid (DHA), and ASARCO oil (DSM Nutritional Products Inc., Parsippany, NJ), and
107 egg phospholipids were used as control samples.

108 **The preparation of extracellular vesicles (EVs) from *E. coli* and *L. plantarum***

109 EVs were isolated from the culture supernatants of *E. coli* (KCTC 1039) and *L. plantarum* (KCTC
110 3108), as described previously (Lee et al. 2009; Kim et al. 2015). Briefly, *E. coli* and *L. plantarum* in
111 nutrient broth was cultured at 37°C and centrifuged twice at 10,000 × g for 15 min. Supernatants were
112 filtered with a 0.22-µm vacuum filter. Then The resulting filtrate was subjected to ultracentrifugation
113 at 150,000 × g for 3 h at 4°C (Beckman Instruments, Fullerton, CA). EVs were diluted in PBS and
114 stored at -80°C.

115 **Anti-inflammatory effect of WPL**

116 The murine macrophage cell line, RAW 264.7 was obtained from the Korea Cell Line Bank (KCLB)
117 and cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin. The cells were incubated
118 at 37°C and 5% CO₂. The cell viability after WPL treatment was measured by MTT assay. Inflammation
119 was induced by treating RAW 264.7 cells with 1 µg/mL of extracellular vesicles (EVs) from *E. coli* and
120 0.1–100 µg/mL of WPL for 24 h. Cytokines IL-6 and TNF-α secreted in the culture medium were
121 quantified using an ELISA kit (R & D Systems, Minneapolis, MN, USA). For the detection of anti-
122 inflammatory activity, RAW 264.7 cells were seeded onto 12-well plate and treated with either 1 µg/mL
123 of EV from *E. coli* along with 0.1–100 µg/mL of WPL, or 1 µg/mL of EV from *Lactobacillus plantarum*
124 and incubated for 24 h at 37°C. The cytokines IL-6 and TNF-α secreted in the culture medium were
125 quantified using an ELISA Kit (R & D Systems).

126 **Statistical analysis**

127 All experiments were repeated three times, and the results were expressed as mean ± standard
128 deviation. Statistical analysis was performed using the SPSS 10.0 program to determine the significance
129 of each treatment (p<0.05) by using the analysis of variance (ANOVA) along with Duncan's multiple

130 range test.

131 **Results and discussion**

132 **Composition of butter serum and whey powder**

133 Table 1 shows the results of the component analysis of butter serum and whey powder, used as raw
134 materials for the preparation of polar lipids. The fat content of butter serum was 27.5% and 12.5% for
135 butter serum powder A and B, respectively, while WPC60 and 70 showed 25.3% and 20.3% fat,
136 respectively. Butter serum powder (A 38.4% and B 46.8%) had higher lactose content than whey
137 (WPC60 1.2% and WPC70 1.5%).

138 Milk PLs can be recovered from whey, or butter serum, the by-products of cheese, or cream-making,
139 respectively. In the production of butter, MFGM fragments damaged by mechanical treatment are
140 recovered in buttermilk or butter serum (Vanderghem et al., 2010). The MFGM fragments obtained as
141 by-products of milk processing include PLs (glycerophospholipids and sphingolipids), neutral lipids
142 (triacylglycerols), proteins, and glycoproteins (Dewettinck et al., 2008; Lopez, 2011). Buttermilk and
143 butter serum has been reported to contain about 2 and 8 g/L of phospholipids, respectively (Rombaut
144 and Dewettinck, 2006). According to a previous report (Boyd et al., 1999), commercial whey powders
145 contain high proportion of lactose, ash, and calcium, but contain low proportion of protein and total
146 lipids, and low protein-to-lipid ratios. The difference in composition is due to differences in the
147 manufacturing processes or in the sources of whey.

148 **Phospholipid content of the polar lipid-enriched fraction after ethanol extraction from butter** 149 **serum and whey powder**

150 Phosphorus content of the polar lipid-enriched fraction, obtained by extracting polar lipids from the
151 by-products with alcohol, was measured (Table 2). The phospholipid content of the enriched fraction
152 obtained from butter serum (A 36.7% and B 45.1%) was higher than that of whey powder (WPC60
153 30.5% and WPC70 31.0%). The yields were 21.0% and 12.0% for butter serum A and B, respectively,
154 and 20.0% and 18.0% for WPC60 and WPC70, respectively (Table 2). Due to its high yield and

155 phospholipid content butter serum powder A was considered to be suitable for the preparation of polar
156 lipid-enriched fraction. Whey powder did not have a detectable lactose content in the polar fraction, and
157 the protein content was lower than that of butter serum. Although WPC60 showed slightly lower
158 phospholipid content and yield, it was selected as a raw material for the production of polar lipid-
159 enriched fraction, in consideration of the economic aspects.

160 For the preparation of polar lipid fractions from MFGM fragments, it is preferable to use butter serum
161 (Rombaut et al., 2006a) and whey (Rombaut et al., 2007a), which contain no or low amounts of casein.

162 **Optimal addition of whey powder for polar lipid production**

163 The effect of ethanol extraction concentration with the change of the solids content was measured
164 to determine the ethanol concentration and the amounts of solids for the extraction of polar lipids (Fig.
165 1). As the solid content of whey powder for extraction increased, the amount of polar lipid extraction
166 increased. As the water content in ethanol increased, the content of polar lipids increased, and the
167 phospholipid content increased. The main lipids contained in the polar lipid fraction were SM and PE,
168 followed by PC (Fig. 1). The major components of polar lipids that make up MFGM are phospholipids
169 (phosphatidylcholine, PC; phosphatidylethanolamine, PE; phosphatidylserine, PS; and
170 phosphatidylinositol, PI) and sphingolipids (mainly sphingomyelin, SM) (Mather, 2000; Ye et al., 2002).

171 In particular, the highest PL content previously reported in dairy products was 45.8% on a dry basis
172 in whey protein extracted with 70% ethanol at 70°C treatment (Price et al., 2018). According to the
173 results presented in Figure 1, the addition of 15.0 and 16.6% of whey powder and the use of 85% alcohol
174 as the extraction solvent are the most suitable conditions for the extraction of 51.1 and 53.3% of PL,
175 respectively.

176 **Lipid composition of polar lipids produced in the optimal process**

177 After the selection of whey powder and extraction solvent, the extraction time and temperature were
178 determined to be 60°C and 30 min, respectively, to establish an optimal process (data not shown). Figure
179 2 shows an optimized extraction process for polar lipid WPL. The optimal production process (Fig. 2)

180 yielded 40.26 kg of polar lipid product, WPL, using 200 kg of whey powder.

181 The lipid composition of WPL is shown in Table 3. The polar lipid content was 38.6%, and PC, SM,
182 and PE showed 14.6%, 10.7%, and 10.1%, respectively. The PS and PI were found in low levels, 1.4%
183 and 1.8%, respectively (Table 3). Polar lipid WPL is composed of phospholipids (mainly PC and PE)
184 and sphingolipids (mainly SM). It also contains small amounts of glycolipids (Cerebroside: 9.79 mg/g,
185 LacCer: 5.50 mg/g, GM3: 0.88 mg/g, GD3: 1.35 mg/g) in Table 4.

186 It has been reported that the concentration of polar lipids in crude oil is between 9.4 and 35.5 mg/100
187 g. The main milk phospholipids are PE (19.8–42.0%, w/w), PC (19.2–37.3%, w/w), PS (1.9–10.5%,
188 w/w), and PI (0.6–11.8%, w/w) (Rombaut et al., 2005; Rombaut and Dewettinck, 2006). The main milk
189 sphingolipids are GluCer (2.1–5.0%, w/w), LacCer (2.8–6.7%, w/w), and SM (18.0–34.1%, w/w).
190 Monosialoganglioside 3 (GM3) and disialoganglioside 3 (GD3) are the major glycolipids of milk and
191 these gangliosides have been reported to contain 0.14 to 1.10 mg/100 mL (Pan and Izumi, 2000).
192 Analysis of polar lipids of whey (Rombaut et al., 2007b), a by-product of mozzarella cheese production,
193 revealed the presence of 40.6% PE, 19.1% PC, and 15.7% SM. In addition, analysis of LacCer content
194 revealed a high level in lipids (8.5%). The content was slightly different from that of WPL. This is
195 likely due to differences in raw milk and differences in the manufacturing process of whey obtained as
196 a by-product.

197 **Rancimat test of WPL**

198 In general, after induction, oil rapidly increases the oxygen absorption rate and oxidation product.
199 Accordingly, rancidity is caused by various physical and chemical changes in oil. Therefore, when the
200 induction time is long, it can be said that the oxidation stability is excellent (Nam et al., 2007). In order
201 to evaluate WPL oxidation stability, DHA and WPL or ARASCO oil or egg phospholipids were mixed,
202 and oxidation induction time was measured by rancimat test (Fig. 3). The oxidation induction time is
203 the time until the conductivity curve reaches the inflection point. Induction times of DHA alone, DHA-
204 ARASCO oil mixture, and DHA-egg phospholipids oil mixture were 0.66 h, 1.91 h, and 4.20 h,
205 respectively. However, induction time was not measured in DHA and WPL oil mixture.

206 The oil mixture of DHA and WPL has a high induction time due to the effect of WPL addition to
207 DHA. There are many studies on the antioxidant properties of PL (Jung et al., 2001; Segawa et al., 1995;
208 King et al., 1992), and not only PL but especially PE and PC can give excellent oxidation stability. This
209 is because the primary amino group of PE contained in polar lipid reacts with the reactive carbonyl
210 produced during heating to produce pyrolyzed phospholipids and heterocyclic moieties with anti-
211 oxidative properties. In addition, the amino groups of PE and PC can promote hydrogen or electron
212 donation to tocopherols (Ramadan et al., 2003). In the previous study, the sum of PE and PC contents
213 extracted from ethanol from whey protein was 32.4% and 21.1%, respectively, of 80% and 90% ethanol
214 (Price et al., 2018). In this study, the sum of PE and PC contents of polar lipid fraction extracted from
215 WPL was 33.9%. Therefore, it was confirmed that the oxidation stability was excellent due to the high
216 content of PE and PC as well as PL.

217 **Anti-inflammatory activity of WPL**

218 The MTT assay was performed to determine the cytotoxicity of WPL in mouse macrophages, RAW
219 264.7. Treatment with increasing concentrations of WPL did not affect cell viability (Fig. 4). Therefore,
220 the subsequent experiments, performed with 100 µg/mL WPL, did not affect the cell viability. This
221 suggests that the anti-inflammatory effect of WPL is not due to a decrease in cell viability, but due to
222 the inherent activity of WPL. Treatment with 0.1 µg/mL of EV for inducing inflammation in RAW
223 264.7 cells resulted in increased production of IL-6 and TNF. It was confirmed that inflammation was
224 caused by EV. However, when WPL was treated with macrophages, IL-6 and TNF were hardly
225 produced, indicating that WPL had no inflammatory effect.

226 During the inflammatory reactions, nitric oxide, TNF- α , and IL-6 are produced, which play an
227 important role in defense against early infection (Higuchi et al., 1990). Prokaryotic or eukaryotic cells
228 secrete extracellular vesicles, and the secreted extracellular vesicles have been reported to have several
229 functions. Extracellular vesicles secreted by gram-negative bacteria contain lipopolysaccharides (LPS)
230 and bacterial proteins. The EVs from gram-negative bacteria are known to induce inflammatory
231 diseases (Lee et al., 2007; Lee et al., 2009).

232 Inflammatory cytokines play a significant role as indicators of inflammation. Therefore, the effect
233 of WPL on the production of inflammatory cytokines (IL-6 and TNF- α) induced by EVs from *E. coli*
234 in RAW 264.7 cells was measured (Fig. 5). The EVs produced by *L. plantarum*, having anti-
235 inflammatory activity, were used as a positive control, which decreased the production of IL-6 and
236 TNF- α . In addition, IL-6 and TNF- α increased upon treatment with EVs from *E. coli* and decreased
237 along with increasing concentration of WPL. Thus, WPL was confirmed to have anti-inflammatory
238 activity. The effect of EVs from *L. plantarum* in the prevention or inhibition of inflammation has
239 already been reported in many studies (Kim et al., 2018; Molina-Tijeras et al., 2019).

240 Phosphatidylserine, a type of polar lipid, has been reported to act as an endogenous modulator of
241 immune and anti-inflammatory responses (Gaitonde et al., 2011; Yamazaki et al., 1997). The anti-
242 inflammatory effects of PC and LysoPC on chronic inflammatory ulcerative colitis have also been
243 reported (Toekes et al., 2010). Milk fats containing a large amounts of MFGM have been reported to
244 have an anti-inflammatory effect on LPS-induced inflammation in the gastrointestinal tract (Snow et
245 al., 2011). There are increasing reports on the regulation of inflammatory responses and treatment of
246 inflammatory diseases through PL intake.

247 **Conclusions**

248 In this study, a solvent extraction and fractionation process was developed to concentrate polar lipids
249 from whey and butter processing derived by-products. In addition, it has been shown that the
250 corresponding polar lipids can greatly contribute to enhancing the oxidation stability of the functional
251 polyunsaturated fatty acids, represented by fish oil. It is believed that by investigating the anti-
252 inflammatory effects in macrophages, milk-derived polar lipids can be effectively used for promoting
253 intestinal health and alleviating inflammatory diseases. Milk-derived polar lipids, unlike the commonly
254 distributed plant-derived polar lipids, contain substantial amounts of sphingomyelin, glycosyl-ceramide,
255 and phosphatidylserine. In the future, diverse innovations would be required, such as 1) the
256 development of an active material for topical product through conversion of sphingomyelin and 2) the

257 development of a cognitive functional product using sphingomyelin and phosphatidylserine.

258 **Conflict of Interest**

259 The authors declare no potential conflict of interest.

260 **Author Contributions**

261 Conceptualization: Suh HJ. Data curation: Jo KA. Formal analysis: Jo KA. Methodology: Suh HJ.

262 Software: Hong KB. Validation: Lee KY. Investigation: Kim A. Writing - original draft: Suh HJ.

263 Writing - review & editing: Lee KH, Kim A, Hong KB, Suh HJ, Jo KA.

264

265 **References**

266 Astaire J, Ward R, German J, Jimenez-Flores R. 2003. Concentration of polar MFGM lipids from
267 buttermilk by microfiltration and supercritical fluid extraction. *J Dairy Sci* 86:2297-2307.

268 Bourlieu C, Cheillan D, Blot M, Daira P, Trauchessec M, Ruet S, Gassi J-Y, Beaucher E, Robert B,
269 Leconte N. 2018. Polar lipid composition of bioactive dairy co-products buttermilk and butterserum:
270 Emphasis on sphingolipid and ceramide isoforms. *Food Chem* 240:67-74.

271 Boyd LC, Drye NC, Hansen AP. 1999. Isolation and characterization of whey phospholipids. *J Dairy*
272 *Sci* 82:2550-2557.

273 Cha G-S, Choi C-U. 1990. Determination of oxidation stability of perilla oil by the rancimat method.
274 *Korean J Food Sci Technol* 22:61-65.

275 Contarini G, Povo M. 2013. Phospholipids in milk fat: Composition, biological and technological
276 significance, and analytical strategies. *Int J Mol Sci* 14:2808-2831.

277 Dewettinck K, Rombaut R, Thienpont N, Le TT, Messens K, Van Camp J. 2008. Nutritional and
278 technological aspects of milk fat globule membrane material. *Int Dairy J* 18:436-457.

279 El-Loly M. 2011. Composition, properties and nutritional aspects of milk fat globule membrane-a
280 review. *Pol J Food Nutr Sci* 61:7-32.

281 Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. 2011. Phosphatidylserine reduces

282 immune response against human recombinant factor viii in hemophilia a mice by regulation of
283 dendritic cell function. Clin Immunol 138:135-145.

284 Gassi JY, Blot M, Beaucher E, Robert B, Leconte N, Camier B, Rousseau F, Bourlieu C, Jardin J, Briard-
285 Bion V. 2016. Preparation and characterisation of a milk polar lipids enriched ingredient from fresh
286 industrial liquid butter serum: Combination of physico-chemical modifications and technological
287 treatments. Int Dairy J 52:26-34.

288 Higuchi M, Higashi N, Taki H, Osawa T. 1990. Cytolytic mechanisms of activated macrophages - tumor
289 necrosis factor and l-arginine-dependent mechanisms act synergistically as the major cytolytic
290 mechanisms of activated macrophages. J Immunol 144:1425-1431.

291 Idf. 1983. International-dairy-federation - milk, cream and evaporated milk - determination of total
292 solids content (reference method) - provisional international idf standard 21a-1982.
293 Milchwissenschaft 38:21-22.

294 Idf. 1996. Idf-fil. International standard 1d. Determination of fat content-gravimetric method (rose-
295 gottlieb reference method). International Dairy Federation Brussels.

296 Idf. 2001. Milk: Determination of nitrogen content (kjeldahal method). Idf standard 20-a. International
297 Dairy Federation, Brussels, Belgium.

298 Jung U, Lee SK, Hum S, Chung GH, Chung M, Lee CH. Antioxidant effects of natural lecithin on
299 borage oil. Food Sci Biotechnol 10:354-359.

300 Kim MH, Choi SJ, Choi HI, Choi JP, Park HK, Kim EK, Kim MJ, Moon BS, Min TK, Rho M, Cho YJ,
301 Yang S, Kim YK, Kim YY, Pyun BY. 2018. *Lactobacillus plantarum*-derived extracellular vesicles
302 protect atopic dermatitis induced by staphylococcus aureus-derived extracellular vesicles. Allergy
303 Asthma Immunol Res 10:516-532.

304 Kim YS, Lee WH, Choi EJ, Choi JP, Heo YJ, Gho YS, Jee YK, Oh YM, Kim YK. 2015. Extracellular
305 vesicles derived from gram-negative bacteria, such as *Escherichia coli*, induce emphysema mainly
306 via IL-17A-mediated neutrophilic inflammation. J Immunol Res 194:3361-3368.

307 King MF, Boyd LC, Sheldon BW. 1992. Antioxidant properties of individual phospholipids in a salmon

308 oil model system. *J Am Oil Chem Soc* 69:545-551.

309 Le TT, Miocinovic J, Nguyen TM, Rombaut R, Van Camp J, Dewettinck K. 2011. Improved solvent
310 extraction procedure and high-performance liquid chromatography-evaporative light-scattering
311 detector method for analysis of polar lipids from dairy materials. *J Agric Food Chem* 59:10407-
312 10413.

313 Lee EY, Bang JY, Park GW, Choi DS, Kang JS, Kim HJ, Park KS, Lee JO, Kim YK, Kwon KH, Kim
314 KP, Gho YS. 2007. Global proteomic profiling of native outer membrane vesicles derived from
315 *Escherichia coli*. *Proteomics* 7:3143-3153.

316 Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, Kim SH, Desiderio DM, Kim YK, Kim KP, Gho
317 YS. 2009. Gram-positive bacteria produce membrane vesicles: Proteomics-based characterization
318 of staphylococcus aureus-derived membrane vesicles. *Proteomics* 9:5425-5436.

319 Lopez C. 2011. Milk fat globules enveloped by their biological membrane: Unique colloidal assemblies
320 with a specific composition and structure. *Curr Opin Colloid In* 16:391-404.

321 Mather IH. 2000. A review and proposed nomenclature for major proteins of the milk-fat globule
322 membrane. *J Dairy Sci* 83:203-247.

323 Molina-Tijeras JA, Galvez J, Rodriguez-Cabezas ME. 2019. The immunomodulatory properties of
324 extracellular vesicles derived from probiotics: A novel approach for the management of
325 gastrointestinal diseases. *Nutrients* 11:1-15.

326 Nam H-Y, Lee J-W, Hong J-H, Lee K-T. 2007. Analysis of physicochemical characterization and
327 volatiles in pure or refined olive oils. *J Korean Soc Food Sci Nutr* 36:1409-1416.

328 Pan XL, Izumi T. 2000. Variation of the ganglioside compositions of human milk, cow's milk and infant
329 formulas. *Early Hum Dev* 57:25-31.

330 Price N, Fei T, Clark S, Wang T. 2018. Extraction of phospholipids from a dairy by-product (whey
331 protein phospholipid concentrate) using ethanol. *J Dairy Sci* 101:8778-8787.

332 Ramadan MF, Kroh LW, Morsel JT. 2003. Radical scavenging activity of black cumin (*Nigella sativa*
333 l.), coriander (*Coriandrum sativum* l.), and niger (*Guizotia abyssinica* cass.) crude seed oils and oil

334 fractions. *J Agric Food Chem* 51:6961-6969.

335 Rombaut R, Camp JV, Dewettinck K. 2005. Analysis of phospho- and sphingolipids in dairy products
336 by a new hplc method. *J Dairy Sci* 88:482-488.

337 Rombaut R, Camp JV, Dewettinck K. 2006a. Phospho- and sphingolipid distribution during processing
338 of milk, butter and whey. *Int J Food Sci Technol* 41:435-443.

339 Rombaut R, Dejonckheere V, Dewettinck K. 2006b. Microfiltration of butter serum upon casein micelle
340 destabilization. *J Dairy Sci* 89:1915-1925.

341 Rombaut R, Dejonckheere V, Dewettinck K. 2007a. Filtration of milk fat globule membrane fragments
342 from acid buttermilk cheese whey. *J Dairy Sci* 90:1662-1673.

343 Rombaut R, Dewettinck K. 2006. Properties, analysis and purification of milk polar lipids. *Int Dairy J*
344 16:1362-1373.

345 Rombaut R, Dewettinck K, Van Camp J. 2007b. Phospho- and sphingolipid content of selected dairy
346 products as determined by hplc coupled to an evaporative light scattering detector (hplc-elsd). *J*
347 *Food Compos Anal* 20:308-312.

348 Segawa T, Kamata M, Torani HY. 1995. Antioxidant activity of phospholipids for polyunsaturated fatty
349 acids of fish oil. III. Synergism of nitrogen-containing phospholipids with tocopherols. *J Jpn Oil*
350 *Chem Soc* 44:36-42.

351 Snow DR, Ward RE, Olsen A, Jimenez-Flores R, Hintze KJ. 2011. Membrane-rich milk fat diet provides
352 protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. *J Dairy Sci*
353 94:2201-2212.

354 Toekes T, Eroes G, Varszegi S, Hartmann P, Bebes A, Kaszaki J, Gulya K, Boros M. Protective effects
355 of phosphatidylcholine pretreatment in endotoxin-induced systemic inflammation in the rat
356 hippocampus. *Acta Physiol Hung*. p[^]pp 483-483.

357 Vanderghem C, Bodson P, Danthine S, Paquot M, Deroanne C, Blecker C. 2010. Milk fat globule
358 membrane and buttermilks: From composition to valorization. *Biotechnol Agron Soc* 14:485-500.

359 Yamazaki M, Inoue A, Koh C-S, Sakai T, Ishihara Y. 1997. Phosphatidylserine suppresses theiler's

360 murine encephalomyelitis virus-induced demyelinating disease. *J Neuroimmunol* 75:113-122.

361 Ye A, Singh H, Taylor MW, Anema S. 2002. Characterization of protein components of natural and
362 heat-treated milk fat globule membranes. *Int Dairy J* 12:393-402.

363 Zygmunt LC, Anderson E, Behrens B, Bowers R, Bussey M, Cohen G, Colon M, Deis C, Given PS,
364 Granade A, Harms C, Heroff JC, Hines D, Hung GW, Hurst WJ, Keller J, Laroche FB, Luth W,
365 Mckay D, Mertle T, Navarre M, Rivera R, Scopp R, Scott F, Sherman R, Sloman K, Sodano C,
366 Trick KD, Vandine BR, Webb NG. 1982. High pressure liquid chromatographic determination of
367 mono- and disaccharides in presweetened cereals: Collaborative study. *J Assoc Off Anal Chem*
368 65:256-264.

ACCEPTED

369 **Figure Captions**

370 **Fig. 1. Lipid composition of polar lipids-enriched fraction from whey serum (WPC60) with**
371 **varying solid content.**

372 **Fig. 2. WPL manufacture process with polar lipid-enriched fraction from whey serum.**

373 **Fig. 3. Measurement of change in induction time by rancimat test with addition of WPL.**

374 **Fig. 4. Effect of WPL on viability and inflammatory cytokine activity of RAW 264.7 cells. RAW**
375 **264.7 cells (1×10^6 cells/mL) were pre-incubated for 24 h and were stimulated with EV (1 μ g/mL)**
376 **or WPL (0.1–100 μ g/mL) for 24 h. Values are presented as the means \pm standard deviation for**
377 **each group.**

378 **Fig. 5. Anti-inflammatory effect of WPL in RAW 264.7 cells. Raw 264.7 cells (1×10^6 cells/mL) were**
379 **pre-incubated for 24 h and were stimulated with EV (1 μ g/mL) in the presence of WPL (0.1–100**
380 **μ g/mL) for 24 h. Values are presented as the means \pm standard deviation for each group. Different**
381 **letters indicate significant differences ($p < 0.05$) among samples by Duncan's multiple range test.**

382

383

384 **Table 1. Chemical composition of butter serum and whey serum**

385

Index	Butter serum		Whey serum	
	Butter serum powder A (%)	Butter serum powder B (%)	WPC60 (%)	WPC70 (%)
Water	1.9	3.3	2.5	1.8
Total fat	27.5	12.5	25.3	20.3
Protein	26.0	28.5	62.5	72.2
Lactose	38.4	46.8	1.2	1.5
Ashes	5.8	7.0	3.0	3.3

386

ACCEPTED

387 **Table 2. Phospholipid content of polar lipid-enriched fraction after ethanol extraction from butter**
 388 **serum and whey serum**
 389

Serum	Butter serum powder A (%)	Butter serum powder B (%)	WPC60 (%)	WPC70 (%)
PL	36.7 ± 1.8	45.1 ± 3.5	30.5 ± 1.8	31.0 ± 0.9
Glycolipids	8.6 ± 0.8	1.6 ± 0.1	5.4 ± 0.2	7.0 ± 0.2
Lactose	5.1 ± 1.3	7.5 ± 0.9	n.d.	n.d.
Crude protein	7.6 ± 0.6	9.7 ± 0.9	5.0 ± 0.6	5.4 ± 0.4
Yield	21.0 ± 1.1	12.0 ± 0.8	20.0 ± 0.9	18.0 ± 0.6

390
 391 Polar lipid-enriched fraction was obtained by adding 95% ethanol 7 times to the serum during a 1 h
 392 extraction at 25°C.
 393

394 **Table 3. Polar lipids composition of WPL as polar lipid-enriched fraction from whey serum**
395 **(WPC60)**

396

Sample	PS (%)	SM (%)	PC (%)	PE (%)	PI (%)	PL (%)
WPL (PL-enriched fraction)	1.36	10.74	14.56	10.08	1.82	38.56

397

398 PS, phosphatidylserine; SM, sphingomyelin; PC, phosphatidylcholine; PE, phosphatidylethanolamine;

399 PI, phosphatidylinositol; PL, phospholipid

400

ACCEPTED

401 **Table 4. Glycolipids composition of WPL as polarlipid-enriched fraction from whey serum**
402 **(WPC60)**

403

Sample	Concentration ($\mu\text{g}/\text{mg}$)			
	Cerebroside	LacCer	GM3	GD3
WPL	9.79 ± 0.78	5.50 ± 0.35	0.88 ± 0.01	1.35 ± 0.01


404

405 LacCer, Lactosylceramide; GM3, monosialoganglioside 3; GD3, disialoganglioside 3

406

ACCEPTED

407



408

409

410

411

Fig. 1.

412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437





Fig. 2.



438


439

440

441

Fig. 3.

442




443

444

445 **Fig. 4.**

446



447

448 **Fig. 5.**